Black Men Less Likely to Get Prostate MRI After Receiving Elevated PSA Score

A study of nearly 800,000 men found that between 2011 and 2017 black patients were 24% less likely than white patients to have a prostate MRI after receiving an elevated (prostate-specific antigen) PSA score. For patients with an elevated PSA, use of prostate MRI prior to prostate biopsy has increased substantially in recent years as MRI can improve identification of clinically significant prostate cancer and obviate the need for biopsy, thus decreasing overdiagnosis of these cases.

The Harvey L. Neiman Health Policy Institute study, published in JAMA Network Open, was based on 794,809 men, age 40 or older, with a PSA test using claims data from the Optum Clinformatics Data Mart Database. Of these men, 51,500 had an PSA score >4ng/mL. The study found that patients with Medicare compared to commercial insurance were less likely to have a prostate MRI as were patients with HMO insurance plans compared to other plan types.

“Compared to White patients, Black, Hispanic, and Asian patients were significantly less likely to undergo prostate MRI within 180 days after an elevated PSA result”, said first author Nino Abashidze, PhD, postdoctoral researcher at the University of Wyoming. Specifically, black patients were 24% and 35% less likely than white patients to have a prostate MRI for those with PSA >4 and >10, respectively. Hispanic patients with PSA >10 were 23% less likely than white patients to have a prostate MRI and Asian patients with PSA>4 were 24% less likely than white patients. “These large racial and ethnic disparities highlight the need for additional research to better understand and mitigate clinical decision-making biases and other potential sources of these disparities, such as physician characteristics or biases in the health care system.”

“Interestingly, the racial and ethnic disparities observed were insignificant among patients over 75 years of age – a population for which the US Preventive Services Task Force recommends against screening for prostate cancer,” said senior author Danny Hughes, PhD, Director of Georgia Tech’s Health Economics & Analytics Lab (HEAL) and NHPI Senior Research Fellow. Significant differences between whites and black, Hispanic, and Asian patients were found at all other age groups (40-54, 55-64, 65-74) but not for those 75 or more. “This indicates the important role that clearly defined guidelines can play in addressing racial and ethnic disparities in care. For the age groups for which prostate cancer screening is recommended, clearer guidelines are still needed for the optimal use of prostate MRI.”